Kraig Biocraft Laboratories (KBLB) Cash & Equivalents (2010 - 2026)

Kraig Biocraft Laboratories has reported Cash & Equivalents for 16 years, with the latest figure at $1.9 million in Q4 2025.

• Quarterly Cash & Equivalents rose 54.07% year-over-year to $1.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.9 million (up 54.07% YoY) and the FY2025 annual result came in at $1.9 million, up 54.07% from the prior year.
• Cash & Equivalents grew to $1.9 million in Q4 2025 per KBLB's latest filing, from $596936.0 in the prior quarter.
• Over five years, Cash & Equivalents peaked at $4.8 million in Q2 2022 and troughed at $397001.0 in Q1 2025.
• A 5-year average of $2.4 million and a median of $2.5 million in 2021 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2021 and 2025: Cash & Equivalents surged 6603.6% in 2021, then tumbled 80.61% in 2025.
• Over 5 years, Cash & Equivalents stood at $2.4 million in 2021, then surged by 64.02% to $3.9 million in 2022, then fell by 24.85% to $2.9 million in 2023, then tumbled by 57.46% to $1.2 million in 2024, then surged by 54.07% to $1.9 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $1.9 million, $596936.0, and $766113.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.